Introduction: There is growing interest in autologous fat grafting (AFG) for breast reconstruction. This systematic review examines the range of outcomes used across studies of AFG, their definitions and whether there is a need for a core outcome set to aid reporting. Methods: Following the protocol of our systematic review, a search of 20 databases (1986 to March 2014) returned 35 studies which met the inclusion criteria. These were assessed independently by two authors. Disagreements were resolved by consensus. Results: Of the 35 studies, 27 (77%) were case series, 5 (14.3%) were cohort studies, and 3 (8.6%) were case reports. A total of 51 different outcomes were reported. These studies each reported a median of five separate outcomes (range, 2-14), of which a median of 3 outcomes were defined (range, 0-14). A median of 2 outcomes per paper were prespecified in the study methods (range, 0-12) and a median of only 2 outcomes per paper (range, 0-12) were both defined and prespecified. The most commonly reported outcome in studies of AFG was that of "operative details," reported by 26 studies, and eight different outcome definitions were used. "Cancer recurrence" was reported by 20 studies, with the use of 10 different outcome definitions. Overall, there was a poor proportion of defined and prespecified outcomes that employed a wide range of different outcome definitions. In addition only 14/35 studies stated the number of patients lost to follow-up. Conclusions: There is a need for a core outcomes set for AFG to the breast to minimise outcome and reporting bias and aid evidence synthesis. Our future research will focus in this direction, titled VOGUE or Valid Outcomes for the Grafting of AUtologous Fat to the BrEast study. We invite all those interested to get in touch with the lead author.
geon, but the overall quality of the evidence available in plastic surgery is currently lacking. Although studies may be empirically labeled as high quality by their study design, we have previously found quality to be lacking in a number of domains of research. For example, the methodological quality of randomized controlled trials in plastic surgery requires improvement, with many complying poorly with basic markers of quality. 1, 2 Recently, our group has shown that the reporting of observational studies in plastic surgery is also inadequate and requires significant improvement. 3 The modern-day plastic surgeon thus encounters difficulties when selecting the best evidence from speciality research to inform their practice.
There is growing interest in the use of autologous fat grafting (AFG) for breast reconstruction. Our group recently published a systematic review and meta-analysis of this topic and demonstrated the utility of this technique as assessed across 6 dimensions. 4 While conducting the review, we noticed significant heterogeneity in the outcomes used by the various study authors. Careful selection of outcome measures is necessary if audit and research is to guide everything from the individual patient consultation to wider healthcare policy development. Potter et al 5 found that across 134 studies of breast reconstruction, there were a total of 950 different outcomes used, and less than 20% of these were defined. Furthermore, there was a lack of consistency between studies in how some outcomes were defined. For instance, in Potter et al's study, "fat necrosis" was defined in 22 different ways, either by volume, timing of occurrence, method of diagnosis, or mode of treatment.
The impact of poor outcome reporting is that opportunities for outcome reporting bias exist. This may occur if a study measures multiple outcomes, but selectively reports results based on whether statistical significance was achieved. 6 Lack of consistency of outcomes also results in potentially spurious meta-analysis and evidence synthesis. This followon work looks at the range of outcomes used across the studies we identified in our systematic review, their definitions, and whether there is a need for a core outcome set (COS) to aid reporting in AFG.
METHODS
The methods of our systematic review were PRISMA compliant and have been published previously, including a protocol that was published a priori following peer-review and revision. 7 Following on from this work involving a search of 20 databases from 1986 to March 2014, 35 studies (including 11 non-English Language papers) that met the inclusion criteria for our systematic review were assessed independently by two authors (T.E.P. and G.W.). Disagreements were resolved by consensus or by arbitration of a third author (A.J.F.).
A data extraction form was produced in Microsoft Word 2011 (Microsoft, Redmond, WA). This was used to extract the list of outcomes that each study reported, and whether these outcomes were defined and prespecified in the methods from each paper. The data from the individual study extraction forms were then populated into a Microsoft Excel 2011 database. When reporting the outcomes described by these studies, we also focused specifically on complications.
RESULTS
The number of articles of each study design is described in our prior work. 7 Case series were the most common study design.
Of the results reported by these studies, each reported a median of five separate outcomes (range, [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] , of which a median of three outcomes were defined (Table 1) , (range, 0-14). A median of two outcomes per article was prespecified in the study methods (range, 0-12) and a median of only two outcomes per article (range, 0-12) were both defined and prespecified (Table 1) .
Further critical appraisal of the above studies revealed that 34 of 35 studies recorded the number of patients included in each study; 31 studies recorded the mean participant ages, but only 14 stated the number of patients who were lost to follow-up.
Five studies declared that internal review board/ ethical permissions had been obtained for the study; only two stated whether industry funding existed, and no studies performed a statistical power calculation (see Table 2 ).
A total of 51 unique outcomes were reported across the 35 studies. The most commonly reported outcomes are illustrated in Table 3 , along with the percentage that were defined and prespecified in the methods of these studies. Table 3 also illustrates the number of definitions that existed for each of the most commonly reported outcomes. Table 4 gives examples of the different definitions used for the most common outcomes reported and illustrates some definitions that were more common than others. For example, 20 studies chose to define their operative outcomes with the volume of fat injected, and 16 defined the operative outcomes by the number of lipomodeling sessions that took place. Considering the importance of cancer recurrence, 10 different outcome definitions were use for cancer recurrence across 20 studies (see Table 4 ), and only 30.0% of studies (n = 6) defined and prespecified this outcome.
Outcomes that were consistent included simple descriptors used to define operative techniques. A large proportion of the examined studies reported outcomes with unique definitions that were included in one study alone in the majority of cases (see Table 4 ). Complications were frequently reported (25/35, 71.4%) and exhibited an especially high variability in definitions used, as illustrated in Table 5 . Table 5 demonstrates the inconsistency of definitions between the different studies with regard to complications, as well as for breast lesions. Breast lesions (cysts, liponecrosis, calcification) are included in Table 5 separately, as five studies used "breast lesions" as a definition for complications; others reported and defined breast lesions independently. For example, one study 8 defined complications as "oil cysts, fat necrosis, calcification," compared to other studies which defined breast lesions as identified by "radiographic assessment (magnetic resonance imaging)," 9 or by "histopathology." 10 Table 5 demonstrates that of the 25 studies that reported complications, not only did 16 of 25 not define them, but also there was absolutely no consistency between any of the other studies in the definitions. Each definition given was only used in one study, for example "local infection" in one study, 11 "injection site cysts, subclinical cysts" in another, 12 and "postoperative pain/tightness and poor cosmesis" in yet another. 13 This same trend was seen in the separate definitions of breast lesions, with each definition only being used in one study. Table 6 offers a comparison of outcome reporting and critical appraisal by study design, although the numbers reported are small.
DISCUSSION
Across 35 studies investigating the use of AFG for breast reconstruction after surgery for breast cancer, there is inconsistency in the definitions of outcomes and complications. Fifty-one unique outcomes were reported, and when looking at complications, there was no overlap in the definitions used. At present, there appears to be a lack of consensus regarding what the best outcome measures are when evaluating the safety and efficacy of AFG for breast reconstruction. When examining the most commonly reported outcomes, there is a high degree of variance in the consistency with which all outcomes are defined and prespecified. The numbers of defined and prespecified outcomes for the most common outcomes are disappointing. Complications should ideally be graded using a validated and standardized method, such as the Clavien-Dindo grading system. 14 This will not overcome the issues of observer bias, where one person may feel that redness is simply postoperative erythema, and another a wound infection and hence the treatments used to deal with the complications. There is therefore a need for clearly defined, and preferably objectively measurable, complication measures for use in future AFG studies. The inconsistency in the definition or measurement of commonly reported outcomes that we have identified compounds the task of evidence synthesis and between-study comparison. Since the realization of the importance of consistent outcomes, there have been increasing calls for consensus, consistency, and a COS. 15 A COS is a set of outcomes (agreed through a Delphi Consensus Exercise) that are reported as a minimum in all studies related to a specific area of clinical practice, audit or research. 16 Core outcome sets were originally pioneered in Rheumatoid Arthritis by the Outcome Measures in Rheumatoid Arthritis Clinical Trials Initiative. 17 Aiming to reduce outcome and reporting bias and standardizing a minimum set of outcomes for reporting (together with their agreed definitions) can aid evidence synthesis.
End-point standardization is already being recognized in oncologic breast surgery. Standardized definitions for Efficacy End-Points in adjuvant breast cancer trials were developed by an expert working group to improve the definition of clinical endpoints (e.g. disease free survival and recurrence free intervals). The aim being to provide clarity to each endpoint, thereby reducing the opportunities for confounding during subsequent data synthesis. 18 The Core Outcome Measures in Effectiveness Trials Initiative (www.comet-initiative.org) is a project that aims to promote the development of COS for different conditions. Recently, one has been developed for reconstructive breast surgery. 19 Why is this area so important? AFG is an active research front, regarded by Rohrich et al 20 as the third most important recent innovation in the field of plastic surgery. One of the directions of future work discussed in our systematic review was the potential of AFG to provide a total reconstructive solution for the breast. 4 Khouri et al 21 have recently provided us with data from such experiences to which we have responded. 22 The importance of this area has even led the Plastic Surgery Foundation to develop a General Registry for Autologous Fat Transfer. 23 We now wish to work collegiately with others to help develop a COS for AFG to the breast using a DELPHI consensus technique.
Limitations
The limitations of this study were in the interpretation of results that were not clearly reported by the authors. It was not unusual to discover that some authors did not define their outcomes, or declare them in the methods, then made a statement about results that were not actually reported. This was extremely challenging to interpret, and such results were ultimately ignored because we could not represent them as a formal outcome. The reporting quality of the above studies may therefore be worse than that reported.
A further limitation is the relative paucity of studies that exists in this field, especially high-quality randomized controlled trials. Despite our best efforts, it is theoretically possible that we missed potentially relevant studies, although this is unlikely given the strength of our work was its methodological rigour.
Strengths
Strengths of this work are that it provides readers with an overview of the outcomes related to AFG that other surgeons believe to be of importance. This work is novel and will serve as a reference for future AFG studies to direct their outcome reporting. It was carried out using a peer-reviewed protocol that was registered a priori. The study included foreign language papers after an exhaustive search of 20 databases over a 28-year period with independent screening and extraction. It was performed by an experienced group with training in methodological and reporting quality, systematic review and meta-analysis, and AFG/general plastic surgery.
CONCLUSIONS
Our work demonstrates that overall, there was inconsistency in the definition or measurement of commonly reported outcomes in the studies we assessed. There is a need for a COS for AFG to minimize outcome and reporting bias and aid evidence synthesis. Our future research will focus in this direction, entitled the Valid Outcomes for the 
